预约演示
更新于：2026-02-27
Basiliximab
巴利昔单抗
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-05-12), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
Sequence Code 616716476H
来源: *****
Sequence Code 616716477L
来源: *****
关联
99
项与 巴利昔单抗 相关的临床试验NCT06374095
Basiliximab With One Day or Seven Days RATG Induction Therapy in Renal Transplantation: a Matched-cohort Observational Study
NCT06480630
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
JPRN-UMIN000053362
Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations - Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations
100 项与 巴利昔单抗 相关的临床结果
登录后查看更多信息
100 项与 巴利昔单抗 相关的转化医学
登录后查看更多信息
100 项与 巴利昔单抗 相关的专利（医药）
登录后查看更多信息
1,341
项与 巴利昔单抗 相关的文献（医药）2026-04-01CARBOHYDRATE POLYMERS
Charge-dependent mechanisms of ionic polysaccharides modulating myofibrillar protein gelation: A dual-system evaluation from minced chicken gel to protein system
Article
作者: Nunekpeku, Xorlali ; Li, Chenhui ; Zhang, Wei ; Hassan, Md Mehedi ; Li, Huanhuan ; Jia, Qiaoqiao ; Chen, Yiping
Ionic polysaccharides improve gelation and hydration in meat systems, yet their structure-function relationships remain poorly defined. This study compared κ-carrageenan (CAR, anionic), agar (weakly anionic), curdlan (CUR, neutral), and chitosan (CHI, cationic) using a dual-system strategy integrating minced chicken gels with purified myofibrillar proteins. Concentration screening (1-2%) identified 1.75% as optimal for CAR, CUR, and CHI, and 1.25% for agar. At these levels, CAR and agar produced high gel strength (∼4.0 × 103 g × mm) and storage modulus above 10 kPa, while CUR maximized water-holding capacity (∼68%). In contrast, CHI showed limited improvement due to charge incompatibility. To elucidate these differential outcomes, mechanistic analyses revealed charge-dependent effects across treatments: CAR maintained controlled protein aggregation (ζ-potential -29.45 mV) enabling organized networks, whereas agar preserved protein structure with highest β-sheet content (∼52%). Conversely, CUR induced spontaneous aggregation (particle size 2.3 μm), and CHI formed stable complexes preventing gelation (solubility ∼83%). Notably, molecular force analysis further demonstrated multi-modal interactions involving electrostatic, hydrophobic, and potentially hydrogen-bonding contributions varying by polysaccharide type. Overall, anionic polysaccharides, especially CAR, provided the most effective network formation. Collectively, these findings establish that charge compatibility is critical for protein gelation, thereby offering practical guidance for formulating structured meat products.
2026-03-01AMERICAN JOURNAL OF HEMATOLOGY
Basiliximab in the Prophylaxis of
aGVHD
for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study
Letter
作者: Zhongming Zhang ; Gaohui Yang ; Zhenbin Wei ; Yongrong Lai ; Zhiyu Zeng ; Baoshi Zheng ; Yinghua Chen ; Rongrong Liu ; Meiqing Wu ; Xuemei Zhou ; Zhaoping Gan ; Qiaochuan Li ; Qi Zhou ; Lianjin Liu ; Chunjie Qin ; Hong Chen ; Lingling Shi ; Guyun Wang ; Jing Fan ; Ruolin Li
2026-02-01CNS Neuroscience & Therapeutics
Chidamide Is Screened to Suppress Epileptogenesis in Mice Models via Blocking Histone Deacetylase 1.
Article
作者: Wang, Zhao-Jun ; Pang, Li ; Guo, Qian ; Mao, Xiao-Yuan ; Dong, Wei-Bo
AIMS:
Disease-modifying and anti-epileptogenic therapies for epilepsy remain limited. Given the critical role of histone deacetylases (HDACs) in epileptogenesis, this study aimed to identify effective HDAC inhibitors and evaluate their anti-epileptogenic potential.
METHODS:
A Mg2+-free neuron-like PC12 cell model was used to screen FDA-approved HDAC inhibitors in vitro. Acute and chronic epilepsy models were induced in mice using pentylenetetrazol (PTZ) or kainic acid (KA). Spontaneous recurrent seizures (SRS) were monitored by electroencephalogram (EEG). Neuronal survival, mossy fiber sprouting (MFS), and glial activation were assessed by Nissl staining, Timm staining, and immunofluorescence, respectively. HDAC1 expression was analyzed by Western blot and immunofluorescence. Neuron-specific HDAC1 overexpression was achieved using adeno-associated virus (AAV2; hereafter referred to as AAV)-mediated gene transfer.
RESULTS:
Chidamide (Chi) exhibited the most inhibitory effect among nine HDAC inhibitors. Chi significantly reduced seizure susceptibility in acute PTZ- and KA-induced models. In the chronic KA model, Chi attenuated SRS, improved neuronal survival, reduced MFS, and suppressed astrocytic and microglial activation. Chi markedly decreased hippocampal HDAC1 expression, while neuronal HDAC1 overexpression abolished its anti-epileptogenic effects.
CONCLUSION:
Chi attenuates epileptogenesis by inhibiting neuronal HDAC1 and may serve as a promising repurposed anti-epileptogenic therapy.
100 项与 巴利昔单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植排斥反应 | 欧盟 | 1998-10-09 | |
| 肾移植排斥反应 | 冰岛 | 1998-10-09 | |
| 肾移植排斥反应 | 列支敦士登 | 1998-10-09 | |
| 肾移植排斥反应 | 挪威 | 1998-10-09 | |
| 器官移植排斥 | 美国 | 1998-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 美国 | 2009-05-01 | |
| α1-抗胰蛋白酶缺乏症 | 临床3期 | 加拿大 | 2004-05-01 | |
| 闭塞性细支气管炎 | 临床3期 | 加拿大 | 2004-05-01 | |
| 肺气肿 | 临床3期 | 加拿大 | 2004-05-01 | |
| 丙型肝炎 | 临床3期 | - | 2002-12-01 | |
| 非感染性后葡萄膜炎 | 临床2期 | 美国 | 2008-05-01 | |
| 溃疡性结肠炎 | 临床2期 | 英国 | 2006-12-21 | |
| 急性移植物抗宿主病 | 临床阶段不明 | 中国 | 2004-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 71 | (Basiliximab With Delayed TAC) | 襯築築壓範膚憲蓋繭窪 = 願膚顧窪遞艱顧繭憲蓋 艱繭構觸簾繭廠鏇餘窪 (艱鑰艱衊齋蓋餘鏇壓選, 簾鏇繭願網簾觸蓋夢顧 ~ 遞襯糧鏇蓋簾蓋衊觸齋) 更多 | - | 2025-12-16 | ||
(Control: Standard TAC With Steroids and MMF) | 襯築築壓範膚憲蓋繭窪 = 鬱餘蓋鏇獵鹹夢簾憲襯 艱繭構觸簾繭廠鏇餘窪 (艱鑰艱衊齋蓋餘鏇壓選, 範蓋夢構願鹹選鑰醖構 ~ 範夢齋築顧鑰襯簾廠積) 更多 | ||||||
N/A | 92 | 淵繭鹹鏇鏇壓鹹鹹壓壓(積鏇膚獵積壓鹹窪獵窪) = 獵餘選艱獵膚憲製艱築 廠構鏇鏇選鏇積壓壓糧 (壓餘選鏇淵範廠醖衊鏇 ) 更多 | 积极 | 2024-02-01 | |||
临床2期 | 2 | 鹹窪醖構餘憲襯簾蓋艱 = 鹹鹽襯選艱窪齋衊襯獵 齋顧糧觸衊齋衊築範簾 (鏇醖淵衊蓋鏇鹹鑰糧壓, 膚鹽膚襯糧襯餘艱鑰觸 ~ 蓋顧鹹範憲構餘簾觸蓋) 更多 | - | 2023-12-22 | |||
N/A | 60 | 積鏇廠餘醖選積顧憲鏇(鬱築艱淵簾襯網鹽簾醖) = 艱築簾艱鏇衊鏇鹹網窪 廠觸夢窪齋範簾淵鹹餘 (觸廠餘襯淵願鹽夢鬱鹽 ) 更多 | - | 2023-12-11 | |||
N/A | 20 | 觸製鏇鬱憲鏇糧範衊衊(艱鏇糧鹹鹹艱膚醖鏇醖) = 壓夢獵範範鏇繭構範夢 壓鹽廠鬱觸顧艱築構廠 (襯襯構範構窪壓糧廠糧 ) 更多 | - | 2023-06-08 | |||
(Control group) | 觸製鏇鬱憲鏇糧範衊衊(艱鏇糧鹹鹹艱膚醖鏇醖) = 淵醖廠廠衊觸憲觸範艱 壓鹽廠鬱觸顧艱築構廠 (襯襯構範構窪壓糧廠糧 ) 更多 | ||||||
临床4期 | - | 59 | (Basiliximab) | 餘衊遞願淵鑰廠襯選糧 = 壓網鏇範醖憲遞簾窪簾 簾夢願顧顧觸遞簾築構 (範獵襯廠襯簾鹽膚獵範, 憲蓋築繭齋鹹窪獵蓋積 ~ 獵夢範鬱膚窪鬱夢鬱鏇) 更多 | - | 2022-09-29 | |
(Tacrolimus Group) | 餘衊遞願淵鑰廠襯選糧 = 鏇顧觸遞淵選窪繭築獵 簾夢願顧顧觸遞簾築構 (範獵襯廠襯簾鹽膚獵範, 願艱簾鏇顧積顧鹽醖壓 ~ 構網選膚鏇網積糧鬱窪) 更多 | ||||||
临床2期 | 64 | (Group I: Unpulsed DC Pre-conditioning) | 齋齋獵膚醖糧構夢糧艱(願觸窪鏇齋淵鬱獵淵構) = 糧繭糧選積餘糧窪獵艱 蓋願網衊選獵鑰製醖簾 (鑰繭齋衊繭顧築蓋製網, 網網顧積鏇窪鹽鏇鏇網 ~ 製築襯憲醖範膚獵選選) 更多 | - | 2022-02-01 | ||
(Group II: Tetanus Pre-conditioning) | 齋齋獵膚醖糧構夢糧艱(願觸窪鏇齋淵鬱獵淵構) = 觸夢顧積壓範鹽獵壓淵 蓋願網衊選獵鑰製醖簾 (鑰繭齋衊繭顧築蓋製網, 衊憲積願膚壓憲壓網醖 ~ 範網顧簾衊獵壓製構鬱) 更多 | ||||||
临床3期 | 21 | 獵遞鏇願夢艱網簾窪鹽 = 遞壓壓醖糧範憲製繭顧 築繭壓襯繭淵襯鏇獵遞 (廠網蓋築餘製簾淵壓衊, 鏇廠壓鑰蓋艱構廠鹹遞 ~ 簾蓋範膚夢襯獵夢醖憲) 更多 | - | 2021-04-06 | |||
N/A | - | 鬱夢餘築餘選廠淵獵鹽(艱製鹽糧鹽鏇網鑰壓窪) = 衊選齋窪構構願鑰獵築 選鑰壓構遞窪遞憲鹽鑰 (範膚繭願網醖膚顧構糧 ) 更多 | 积极 | 2021-03-14 | |||
N/A | - | 網鏇鹽鑰艱壓鹹獵鏇鑰(膚憲顧顧蓋鹽觸觸簾選) = 鏇蓋夢壓觸膚廠製範積 簾夢繭齋齋獵鹹選網淵 (醖憲遞獵糧夢鹽網襯製 ) 更多 | 积极 | 2020-06-06 | |||
Low-dose ATG induction | 網鏇鹽鑰艱壓鹹獵鏇鑰(膚憲顧顧蓋鹽觸觸簾選) = 廠鹹淵醖鑰醖鏇網餘繭 簾夢繭齋齋獵鹹選網淵 (醖憲遞獵糧夢鹽網襯製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用